Form 4: Airsculpt CFO Awarded Equity Incentives

Airsculpt Technologies' Chief Financial Officer, Michael J. Arthur, received grants of Restricted Stock Units and Performance Stock Units as part of the company's equity incentive plan.

Summary

• Michael J. Arthur, Chief Financial Officer of Airsculpt Technologies, Inc. (AIRS), was granted 147,059 Restricted Stock Units (RSUs) and 147,059 Performance Stock Units (PSUs) on January 24, 2026.
• The RSUs will vest in three equal annual installments, subject to continued employment, beginning on January 24, 2027.
• The PSUs will vest based on the company's relative total shareholder return (TSR) performance against the S&P Health Care Select Industry Index over a three-year performance period, with potential payout ranging from 0% to 200% of the target award.
• Both awards were granted at a price of $0 under the company's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of equity awards to the CFO is a positive step for aligning management incentives with long-term shareholder value and executive retention. The performance-based nature of the PSUs, tied to relative TSR, is a strong mechanism for driving competitive performance. However, it is a routine compensation event rather than a significant new strategic development.

Positives

• Aligns the Chief Financial Officer's interests with long-term shareholder value through performance-based equity awards.
• The PSU award directly links executive compensation to the company's total shareholder return relative to an industry benchmark, promoting competitive performance.
• The RSU award encourages executive retention through a multi-year vesting schedule.

Negatives

• Potential for future share dilution upon vesting and conversion of the RSUs and PSUs into common stock.
• The value of the awards is contingent on future stock performance and continued employment, introducing personal risk for the executive.

Risks

• The PSUs may not vest or may vest at a reduced percentage (0% to 200%) if the company's total shareholder return does not meet the performance goal relative to the S&P Health Care Select Industry Index over the three-year period.
• The RSUs are subject to forfeiture if the reporting person's employment with the company terminates before the vesting dates.

Future Outlook

The equity awards are designed to incentivize the Chief Financial Officer to drive long-term shareholder value and ensure retention, with vesting tied to both continued employment and relative total shareholder return performance over a multi-year period.

Industry Context

Granting equity awards like RSUs and PSUs is a standard practice in executive compensation across various industries, including healthcare technology, to align management incentives with shareholder interests and promote long-term performance and retention. The use of relative TSR as a performance metric for PSUs is also a common approach to benchmark executive performance against industry peers.

Comparison to Industry Standards

• The structure of these equity awards, including multi-year vesting for RSUs and performance-based vesting tied to relative Total Shareholder Return (TSR) for PSUs, is consistent with best practices in executive compensation within the healthcare and technology sectors.
• Many companies, such as Medtronic (MDT) or Intuitive Surgical (ISRG), utilize similar long-term incentive plans to motivate executives and align their interests with long-term shareholder value.
• The S&P Health Care Select Industry Index is a relevant benchmark for a company like Airsculpt Technologies, ensuring that performance is measured against appropriate industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of equity awards; improved alignment of executive interests with long-term shareholder value.
• Employees: Retention of a key executive (CFO) through long-term incentives.

Next Steps

• Vesting of Restricted Stock Units in three equal annual installments, beginning January 24, 2027.
• Assessment of Performance Stock Units vesting based on relative total shareholder return against the S&P Health Care Select Industry Index at the end of the three-year performance period (January 24, 2029).

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant, which is a standard practice for publicly traded companies to incentivize and retain key management. While the awards align the CFO's interests with shareholder value, this type of transaction typically does not provide new material information that would warrant a change in investment recommendation. Investors should consider this as part of the ongoing compensation structure rather than a catalyst for significant price movement.

Keywords

Airsculpt Technologies, AIRS, Form 4, SEC filing, Restricted Stock Units, Performance Stock Units, RSUs, PSUs, executive compensation, equity incentive plan, insider transaction, Michael J. Arthur, CFO